Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
Abbreviations
ALAT | Alanine aminotransferase |
ASAT | Aspartate aminotransferase |
BMI | Body mass index |
CMV | Cytomegalovirus |
CRP | C-reactive protein |
DAA | Direct antiviral agent |
eGFR | Estimated glomerular filtration rate |
HCV | Hepatitis C virus |
KRT | Kidney replacement therapy |
NAT | Nucleic acid testing |
RNA | Ribonucleic acid |
SVR | Sustained virological response |
γGT | γ-Glutamyltransferase |
References
- Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; O’Callaghan, C.A.; Lasserson, D.S.; Hobbs, F.D. Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis. PLoS ONE 2016, 11, e0158765. [Google Scholar] [CrossRef] [PubMed]
- Francis, A.; Harhay, M.N.; Ong, A.C.M.; Tummalapalli, S.L.; Ortiz, A.; Fogo, A.B.; Fliser, D.; Roy-Chaudhury, P.; Fontana, M.; Nangaku, M.; et al. Chronic kidney disease and the global public health agenda: An international consensus. Nat. Rev. Nephrol. 2024, 20, 473–485. [Google Scholar] [CrossRef] [PubMed]
- Oniscu, G.C.; Brown, H.; Forsythe, J.L. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J. Am. Soc. Nephrol. 2005, 16, 1859–1865. [Google Scholar] [CrossRef] [PubMed]
- Chaudhry, D.; Chaudhry, A.; Peracha, J.; Sharif, A. Survival for waitlisted kidney failure patients receiving transplantation versus remaining on waiting list: Systematic review and meta-analysis. BMJ 2022, 376, e068769. [Google Scholar] [CrossRef]
- Durand, C.M.; Bowring, M.G.; Brown, D.M.; Chattergoon, M.A.; Massaccesi, G.; Bair, N.; Wesson, R.; Reyad, A.; Naqvi, F.F.; Ostrander, D.; et al. Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus-Infected Donors to Noninfected Recipients: An Open-Label Nonrandomized Trial. Ann. Intern. Med. 2018, 168, 533–540. [Google Scholar] [CrossRef]
- Zecher, D.; Tieken, I.; Wadewitz, J.; Zeman, F.; Rahmel, A.; Banas, B. Regional Differences in Waiting Times for Kidney Transplantation in Germany. Dtsch. Arztebl. Int. 2023, 120, 393–399. [Google Scholar] [CrossRef]
- Gill, J.S.; Rose, C.; Pereira, B.J.; Tonelli, M. The importance of transitions between dialysis and transplantation in the care of end-stage renal disease patients. Kidney Int. 2007, 71, 442–447. [Google Scholar] [CrossRef]
- Goldberg, D.S.; Blumberg, E.; McCauley, M.; Abt, P.; Levine, M. Improving Organ Utilization to Help Overcome the Tragedies of the Opioid Epidemic. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2016, 16, 2836–2841. [Google Scholar] [CrossRef]
- Webster, D.P.; Klenerman, P.; Dusheiko, G.M. Hepatitis C. Lancet 2015, 385, 1124–1135. [Google Scholar] [CrossRef]
- Manns, M.P.; Buti, M.; Gane, E.; Pawlotsky, J.M.; Razavi, H.; Terrault, N.; Younossi, Z. Hepatitis C virus infection. Nat. Rev. Dis. Primers 2017, 3, 17006. [Google Scholar] [CrossRef]
- Hoare, M.; Gelson, W.T.; Rushbrook, S.M.; Curran, M.D.; Woodall, T.; Coleman, N.; Davies, S.E.; Alexander, G.J. Histological changes in HCV antibody-positive, HCV RNA-negative subjects suggest persistent virus infection. Hepatology 2008, 48, 1737–1745. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, D.E. Cost/Benefit of Hepatitis C Treatment: It Does Not End with SVR. Dig. Dis. Sci. 2018, 63, 1376–1377. [Google Scholar] [CrossRef]
- Molnar, M.Z.; Nair, S.; Cseprekal, O.; Yazawa, M.; Talwar, M.; Balaraman, V.; Podila, P.S.B.; Mas, V.; Maluf, D.; Helmick, R.A.; et al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: Single center experience. Am. J. Transplant. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2019, 19, 3046–3057. [Google Scholar] [CrossRef] [PubMed]
- Gordon, C.E.; Adam, G.P.; Jadoul, M.; Martin, P.; Balk, E.M. Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: A Systematic Review for the KDIGO 2022 Hepatitis C Clinical Practice Guideline Update. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 2023, 82, 410–418. [Google Scholar] [CrossRef]
- Sise, M.E.; Chute, D.F.; Gustafson, J.L.; Wojciechowski, D.; Elias, N.; Chung, R.T.; Williams, W.W. Transplantation of hepatitis C virus infected kidneys into hepatitis C virus uninfected recipients. Hemodial. Int. Int. Symp. Home Hemodial. 2018, 22 (Suppl. S1), S71–S80. [Google Scholar] [CrossRef] [PubMed]
- Goldberg, D.S.; Abt, P.L.; Blumberg, E.A.; Van Deerlin, V.M.; Levine, M.; Reddy, K.R.; Bloom, R.D.; Nazarian, S.M.; Sawinski, D.; Porrett, P.; et al. Trial of Transplantation of HCV-Infected Kidneys into Uninfected Recipients. N. Engl. J. Med. 2017, 376, 2394–2395. [Google Scholar] [CrossRef]
- Reese, P.P.; Abt, P.L.; Blumberg, E.A.; Van Deerlin, V.M.; Bloom, R.D.; Potluri, V.S.; Levine, M.; Porrett, P.; Sawinski, D.; Nazarian, S.M.; et al. Twelve-Month Outcomes After Transplant of Hepatitis C-Infected Kidneys Into Uninfected Recipients: A Single-Group Trial. Ann. Intern. Med. 2018, 169, 273–281. [Google Scholar] [CrossRef]
- Sise, M.E.; Goldberg, D.S.; Kort, J.J.; Schaubel, D.E.; Alloway, R.R.; Durand, C.M.; Fontana, R.J.; Brown, R.S., Jr.; Friedewald, J.J.; Prenner, S.; et al. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. J. Am. Soc. Nephrol. 2020, 31, 2678–2687. [Google Scholar] [CrossRef]
- Torabi, J.; Rocca, J.P.; Ajaimy, M.; Melvin, J.; Campbell, A.; Akalin, E.; Liriano, L.E.; Azzi, Y.; Pynadath, C.; Greenstein, S.M.; et al. Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients. Transpl. Infect. Dis. Off. J. Transplant. Soc. 2021, 23, e13449. [Google Scholar] [CrossRef]
- Kapila, N.; Menon, K.V.N.; Al-Khalloufi, K.; Vanatta, J.M.; Murgas, C.; Reino, D.; Ebaid, S.; Shaw, J.J.; Agrawal, N.; Rhazouani, S.; et al. Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience. Hepatology 2020, 72, 32–41. [Google Scholar] [CrossRef]
- Reese, P.P.; Abt, P.L.; Blumberg, E.A.; Goldberg, D.S. Transplanting Hepatitis C-Positive Kidneys. N. Engl. J. Med. 2015, 373, 303–305. [Google Scholar] [CrossRef] [PubMed]
- Kolbrink, B.; Kakavand, N.; Voran, J.C.; Zacharias, H.U.; Rahmel, A.; Vogelaar, S.; Schicktanz, S.; Braun, F.; Schmitt, R.; von Samson-Himmelstjerna, F.A.; et al. Allocation Rules and Age-Dependent Waiting Times for Kidney Transplantation. Dtsch. Arztebl. Int. 2024, 121, 559–565. [Google Scholar] [CrossRef]
- Gupta, G.; Yakubu, I.; Bhati, C.S.; Zhang, Y.; Kang, L.; Patterson, J.A.; Andrews-Joseph, A.; Alam, A.; Ferreira-Gonzalez, A.; Kumar, D.; et al. Ultra-short duration direct acting antiviral prophylaxis to prevent virus transmission from hepatitis C viremic donors to hepatitis C negative kidney transplant recipients. Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg. 2020, 20, 739–751. [Google Scholar] [CrossRef]
- Feld, J.J.; Cypel, M.; Kumar, D.; Dahari, H.; Pinto Ribeiro, R.V.; Marks, N.; Kamkar, N.; Bahinskaya, I.; Onofrio, F.Q.; Zahoor, M.A.; et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A phase 3, single-centre, open-label study. Lancet Gastroenterol. Hepatol. 2020, 5, 649–657. [Google Scholar] [CrossRef] [PubMed]
- Woolley, A.E.; Singh, S.K.; Goldberg, H.J.; Mallidi, H.R.; Givertz, M.M.; Mehra, M.R.; Coppolino, A.; Kusztos, A.E.; Johnson, M.E.; Chen, K.; et al. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. N. Engl. J. Med. 2019, 380, 1606–1617. [Google Scholar] [CrossRef] [PubMed]
- Warren, E.; Castles, B.J.C.; Sharratt, G.C.; Arteaga, A. Direct-Acting Antivirals Remain Cost-Effective Treatments for Chronic Hepatitis C in Australia Despite Changes to the Treated Population and the Availability of Retreatment: The Glecaprevir/Pibrentasvir (Maviret®) Example. Infect. Dis. Ther. 2024, 13, 549–564. [Google Scholar] [CrossRef]
- Jandovitz, N.; Nair, V.; Grodstein, E.; Molmenti, E.; Fahmy, A.; Abate, M.; Bhaskaran, M.; Teperman, L. Hepatitis C-positive donor to negative recipient kidney transplantation: A real-world experience. Transpl. Infect. Dis. Off. J. Transplant. Soc. 2021, 23, e13540. [Google Scholar] [CrossRef]
- Graham, J.A.; Torabi, J.; Ajaimy, M.; Akalin, E.; Liriano, L.E.; Azzi, Y.; Pynadath, C.T.; Greenstein, S.M.; Goldstein, D.Y.; Fox, A.S.; et al. Transplantation of viral-positive hepatitis C-positive kidneys into uninfected recipients offers an opportunity to increase organ access. Clin. Transplant. 2020, 34, e13833. [Google Scholar] [CrossRef]
- Franco, A.; Moreso, F.; Solà-Porta, E.; Beneyto, I.; Esforzado, N.; Gonzalez-Roncero, F.; Sancho, A.; Melilli, E.; Ruiz, J.C.; Galeano, C. Outcome of Kidney Transplants from Viremic and Non-Viremic Hepatitis C Virus Positive Donors into Negative Recipients: Results of the Spanish Registry. J. Clin. Med. 2023, 12, 1773. [Google Scholar] [CrossRef]
- Tokumoto, T.; Tanabe, K.; Simizu, T.; Shimmura, H.; Iizuka, J.; Ishikawa, N.; Oshima, T.; Yagisawa, T.; Goya, N.; Nakazawa, H.; et al. Kidney transplantation from a donor who is HCV antibody positive and HCV-RNA negative. Transplant. Proc. 2000, 32, 1597–1599. [Google Scholar] [CrossRef]
- Nowak, K.M.; Witzke, O.; Sotiropoulos, G.C.; Benkö, T.; Fiedler, M.; Timm, J.; Kribben, A.; Wilde, B.; Saner, F.H.; Paul, A.; et al. Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome. Kidney Int. Rep. 2016, 2, 53–59. [Google Scholar] [CrossRef] [PubMed]
All | HCV-AB+/RNA− | HCV-RNA+ | p-Value | |
n = 13 | n = 8 (61.5%) | n = 5 (38.5%) | ||
Age at transplant, median (SD) | 52.85 (11.4) | 48.9 (12.5) | 59.2 (4.3) | 0.13 |
Body mass index (SD) | 26.9 (3.1) | 26.4 (2.8) | 27.76 (3.4) | 0.47 |
Hemodialysis (%) | 13 (100) | 8 (100) | 5 (100) | 0.99 |
Time on HD (months) | 80 (37.4) | 102 (27.3) | 44.6 (20.0) | 0.003 |
Residual diuresis (%) | 8 (61.5) | 6 (75.0) | 2 (40.0) | 0.29 |
Hypertension (%) | 10 (76.9) | 6 (75.0) | 4 (80.0) | 0.99 |
Diabetes (%) | 2 (15.4) | 1 (12.5) | 1 (20.0) | 0.99 |
Cause of End-Stage Kidney Disease | ||||
Cystic disease (%) | 3 (23.0) | 3 (37.5) | 0 (0) | nd |
Diabetes (%) | 2 (15.4) | 1 (12.5) | 1 (20.0) | nd |
Hypertension (%) | 1 (7.7) | 0 (0) | 1 (20.0) | nd |
Congenital anomalies of the kidney and urinary tract (%) | 1 (7.7) | 1 (12.5) | 0 (0) | nd |
Focal segmental glomerulosclerosis (%) | 1 (7.7) | 0 (0) | 1 (20.0) | nd |
Rapidly progressive glomerulonephritis (%) | 1 (7.7) | 0 (0) | 1 (20.0) | nd |
Tubulointerstitial glomerulonephritis (%) | 1 (7.7) | 1 (12.5) | 0 (0) | nd |
Unknown/Not specified (%) | 3 (23.0) | 2 (25.0) | 1 (20.0) | nd |
Ischemia time (min) | 837.2 (389.4) | 750.4 (342.0) | 976.2 (419.0) | 0.35 |
Mismatches | 3.5 (1.2) | 3.6 (1.3) | 3.4 (1.0) | 0.76 |
CMV + recipient (%) | 6 (46.2) | 4 (50.0) | 2 (40.0) | 0.99 |
CMV + donor (%) | 7 (53.8) | 3 (37.5) | 4 (80.0) | 0.27 |
Antiviral Treatment with Glecaprevir/Pibrentasvir | 5 (38.5) | 0 (0) | 5 (100) | 0.001 |
Immunosuppressive Therapy | ||||
Ciclosporin A | 4 (30.1) | 4 (50) | 0 (0) | 0.27 |
Tacrolimus | 9 (69.2) | 4 (50) | 5 (100) | 0.27 |
Mycophenolate mofetil | 13 (100) | 8 (100) | 5 (100) | 0.99 |
Prednisolone | 13 (100) | 8 (100) | 5 (100) | 0.99 |
Basiliximab | 10 (76.9) | 5 (38.5) | 5 (100) | 0.23 |
All | HCV-AB+/RNA− | HCV-RNA+ | p-Value | |
n = 13 | n = 8 (61.5%) | n = 5 (38.5%) | ||
Female sex (%) | 7 (53.84) | 5 (62.50) | 2 (40.00) | 0.59 |
Age at donation, median (SD) | 48.92 (11.65) | 44.25 (11.22) | 56.40 (9.72) | 0.09 |
Creatinine (mg/dL) | 1.00 (0.56) | 1.09 (0.68) | 0.86 (0.28) | 0.32 |
Bilirubin, total (mg/dL) | 0.52 (0.43) | 0.37 (0.15) | 0.78 (0.56) | 0.13 |
ASAT (U/L) | 94.00 (86.06) | 111.37 (114.27) | 66.20 (31.65) | 0.42 |
ALAT (U/L) | 77.23 (95.45) | 98.86 (127.56) | 42.60 (25.47) | 0.36 |
γGT (U/L) | 65.92 (59.3) | 61.375 (66.58) | 73.20 (54.43) | 0.76 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ploeger, L.; Elshoff, P.L.; Kortus-Goetze, B.; Hoyer, J.; Russwurm, M.; Wild, J. Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety. J. Clin. Med. 2025, 14, 2653. https://doi.org/10.3390/jcm14082653
Ploeger L, Elshoff PL, Kortus-Goetze B, Hoyer J, Russwurm M, Wild J. Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety. Journal of Clinical Medicine. 2025; 14(8):2653. https://doi.org/10.3390/jcm14082653
Chicago/Turabian StylePloeger, Lara, Philipp Luetke Elshoff, Birgit Kortus-Goetze, Joachim Hoyer, Martin Russwurm, and Johannes Wild. 2025. "Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety" Journal of Clinical Medicine 14, no. 8: 2653. https://doi.org/10.3390/jcm14082653
APA StylePloeger, L., Elshoff, P. L., Kortus-Goetze, B., Hoyer, J., Russwurm, M., & Wild, J. (2025). Utilization of Organs from Hepatitis C-Antibody-Positive or RNA-Positive Donors in Kidney Transplantation: A Single-Center Retrospective Analysis of Outcomes and Safety. Journal of Clinical Medicine, 14(8), 2653. https://doi.org/10.3390/jcm14082653